Search

Your search keyword '"de Ancos, C."' showing total 45 results

Search Constraints

Start Over You searched for: Author "de Ancos, C." Remove constraint Author: "de Ancos, C."
45 results on '"de Ancos, C."'

Search Results

1. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

2. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

3. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

4. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

5. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

6. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

7. Timing and characteristics of venous thromboembolism after noncancer surgery

8. Comparative clinical prognosis of massive and non‐massive pulmonary embolism: A registry‐based cohort study

9. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

10. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

11. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

12. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

13. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

14. Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐ or therapeutic doses of thromboprophylaxis

15. PO-55: Effectiveness and safety of enoxaparin in the extended treatment of venous thromboembolism in active cancer patients with renal impairment: results from the RIETECAT-RI cohort study

16. Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?

17. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

18. Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry

19. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

20. Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project

21. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry

22. Timing and characteristics of venous thromboembolism after noncancer surgery

23. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

24. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

25. Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry

26. Systolic blood pressure and mortality in acute symptomatic pulmonary embolism

27. Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry

28. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

29. Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE Database

30. Venous thromboembolism in young adults: Findings from the RIETE registry

31. Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry

32. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

33. Fondaparinux in the initial and long-term treatment of venous thromboembolism

34. Unsuspected pulmonary embolism in patients with cancer

35. Venous thromboembolism in patients immobilised at home

36. Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs

37. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

38. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study

39. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

40. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

41. Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry.

42. Seven Epidemic Waves of COVID-19 in a Hospital in Madrid: Analysis of Severity and Associated Factors.

43. Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry.

44. Validation of a Prognostic Score to Identify Hospitalized Patients with COVID-19 at Increased Risk for Bleeding.

Catalog

Books, media, physical & digital resources